Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
70
AZN Quote, Financials, Valuation and Earnings
Last price:
$91.59
Seasonality move
:
1.67%
Day range:
$90.36 - $91.87
52-week range:
$61.24 - $94.02
Dividend yield:
1.71%
P/E ratio:
30.34x
P/S ratio:
4.91x
P/B ratio:
6.17x
Volume:
8.4M
Avg. volume:
5.7M
1-year change:
41.78%
Market cap:
$283.3B
Revenue:
$54.1B
EPS (TTM):
$3.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$14.8B | $1.13 | 4.56% | 128.14% | $98.96 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.49% | 33.42% | $132.38 |
|
GSK
GSK Plc
|
$11B | $1.26 | 8.14% | 137.07% | $49.35 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $789.90 |
|
SNY
Sanofi
|
$14.2B | $1.57 | -6.06% | 28.6% | $59.35 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$91.36 | $98.96 | $283.3B | 30.34x | $0.52 | 1.71% | 4.91x |
|
AMGN
Amgen, Inc.
|
$327.38 | $325.88 | $176.3B | 25.31x | $2.38 | 2.91% | 4.94x |
|
GILD
Gilead Sciences, Inc.
|
$124.29 | $132.38 | $154.2B | 19.25x | $0.79 | 2.54% | 5.38x |
|
GSK
GSK Plc
|
$48.61 | $49.35 | $97.7B | 13.86x | $0.42 | 3.45% | 2.38x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$767.96 | $789.90 | $80.7B | 18.39x | $0.88 | 0.46% | 5.94x |
|
SNY
Sanofi
|
$48.18 | $59.35 | $117.5B | 12.03x | $2.20 | 4.56% | 2.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.56% | 0.163 | 13.71% | 0.66x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
GSK
GSK Plc
|
52.36% | -0.071 | 27.67% | 0.53x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
SNY
Sanofi
|
22.66% | -0.244 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
SNY
Sanofi
|
$8.8B | $1.9B | 9.89% | 12.45% | 14.08% | $218.7M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 33.55%. AstraZeneca PLC's return on equity of 22.01% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 8.31%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -0.46%. Given that AstraZeneca PLC has higher upside potential than Amgen, Inc., analysts believe AstraZeneca PLC is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 AMGNAmgen, Inc.10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Amgen, Inc. offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Amgen, Inc. quarterly revenues of $9.6B. AstraZeneca PLC's net income of $2.5B is lower than Amgen, Inc.'s net income of $3.2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.34x while Amgen, Inc.'s PE ratio is 25.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.91x versus 4.94x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.91x 30.34x $15.1B $2.5B AMGNAmgen, Inc.4.94x 25.31x $9.6B $3.2B
-
Which has Higher Returns AZN or GILD?
Gilead Sciences, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 39.21%. AstraZeneca PLC's return on equity of 22.01% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About AZN or GILD?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 8.31%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.51%. Given that AstraZeneca PLC has higher upside potential than Gilead Sciences, Inc., analysts believe AstraZeneca PLC is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GILDGilead Sciences, Inc.16 8 0 -
Is AZN or GILD More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock AZN or GILD?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Gilead Sciences, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $0.79 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.
-
Which has Better Financial Ratios AZN or GILD?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. AstraZeneca PLC's net income of $2.5B is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.34x while Gilead Sciences, Inc.'s PE ratio is 19.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.91x versus 5.38x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.91x 30.34x $15.1B $2.5B GILDGilead Sciences, Inc.5.38x 19.25x $7.8B $3.1B
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GSKGSK Plc73.8% $1.32 $45.1B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 8.31%. On the other hand GSK Plc has an analysts' consensus of $49.35 which suggests that it could grow by 1.51%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GSKGSK Plc1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.951%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. GSK Plc offers a yield of 3.45% to investors and pays a quarterly dividend of $0.42 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.34x while GSK Plc's PE ratio is 13.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.91x versus 2.38x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.91x 30.34x $15.1B $2.5B GSKGSK Plc2.38x 13.86x $11.5B $2.9B
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 38.89%. AstraZeneca PLC's return on equity of 22.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 8.31%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 2.86%. Given that AstraZeneca PLC has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe AstraZeneca PLC is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. AstraZeneca PLC's net income of $2.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.34x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.91x versus 5.94x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.91x 30.34x $15.1B $2.5B REGNRegeneron Pharmaceuticals, Inc.5.94x 18.39x $3.8B $1.5B
-
Which has Higher Returns AZN or SNY?
Sanofi has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 36.7%. AstraZeneca PLC's return on equity of 22.01% beat Sanofi's return on equity of 12.45%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B SNYSanofi72.13% $1.83 $106.5B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 8.31%. On the other hand Sanofi has an analysts' consensus of $59.35 which suggests that it could grow by 23.19%. Given that Sanofi has higher upside potential than AstraZeneca PLC, analysts believe Sanofi is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 SNYSanofi5 2 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Sanofi has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.394%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.71%. Sanofi offers a yield of 4.56% to investors and pays a quarterly dividend of $2.20 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Sanofi quarterly revenues of $12.2B. AstraZeneca PLC's net income of $2.5B is lower than Sanofi's net income of $4.5B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.34x while Sanofi's PE ratio is 12.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.91x versus 2.77x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.91x 30.34x $15.1B $2.5B SNYSanofi2.77x 12.03x $12.2B $4.5B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
